Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment

Colloids and Surfaces B: Biointerfaces

Volumn 81, Issue 1, 2010, Pages 263-273

  Nayak, Aditya P ^a   Tiyaboonchai, Waree ^b   Patankar, Swati ^c   Madhusudhan, Basavaraj ^a   Souto, Eliana B ^d,e  

^a KUVEMPU UNIVERSITY   (India)

^b NARESUAN UNIVERSITY   (Thailand)

^c INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^e UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Antimalarial agent; Curcuminoids; Nanostructured lipid carriers; Parenteral delivery; Solid lipid nanoparticles

Indexed keywords

ANTIMALARIAL AGENT; CURCUMINOIDS; NANOSTRUCTURED LIPID CARRIERS; PARENTERAL DELIVERY; SOLID LIPID NANOPARTICLES;

DIFFERENTIAL SCANNING CALORIMETRY; NANOCOMPOSITES; PHOTON CORRELATION SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; ULTRASONIC TESTING; ZETA POTENTIAL;

NANOPARTICLES;

ANTIMALARIAL AGENT; CURCUMINOID; GLYCEROL STEARATE; LIPID; MEDIUM CHAIN TRIACYLGLYCEROL; NANOCARRIER; PROPYLENE GLYCOL; SOLID LIPID NANOPARTICLE; TRIMYRISTIN; TRISTERIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; AUTOCLAVE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG STABILITY; HEAT SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MOUSE; NANOEMULSION; NANOENCAPSULATION; NANOFABRICATION; NANOFILTRATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; CURCUMIN; DRUG COMPOUNDING; DRUG STABILITY; GLYCERIDES; HEMOLYSIS; HUMANS; KINETICS; LIPIDS; MALARIA; MICE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; PLASMODIUM BERGHEI; SOLUBILITY; TEMPERATURE; TRIGLYCERIDES;

EID: 77956009968     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.07.020     Document Type: Article

References (50)

1. Edwards G., Krishna S. Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:233-242.
2. Parola P., Pradines B., Simon F., Carlotti M.P., Minodier P., Ranjeva M.P., Badiaga S., Bertaux L., Delmont J., Morillon M., Silai R., Brouqui P., Parzy D. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004 2006. Am. J. Trop. Med. Hyg. 2007, 77:431-437.
3. Huang M.T., Newmark H.L., Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J. Cell. Biochem. Suppl. 1997, 27:26-34.
4. Huang M.T., Ma W., Lu Y.P., Chang R.L., Fisher C., Manchand P.S., Newmark H.L., Conney A.H. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis 1995, 16:2493-2497.
5. Changtam C., de Koning H.P., Ibrahim H., Sajid M.S., Gould M.K., Suksamrarn A. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur. J. Med. Chem. 2010, 45:941-956.
6. Peng C.H., Chiu W.T., Juan C.W., Mau J.L., Chen C.C., Peng C.C., Lai E.Y., Chyau C.C. Pivotal role of curcuminoids on the antimutagenic activity of Curcuma zedoaria extracts. Drug Chem. Toxicol. 2010, 33:64-76.
7. Haukvik T., Bruzell E., Kristensen S., Tonnesen H.H. Photokilling of bacteria by curcumin in different aqueous preparations. Studies on curcumin and curcuminoids XXXVII. Pharmazie 2009, 64:666-673.
8. Aftab N., Vieira A. Antioxidant activities of curcumin and combinations of this curcuminoid with other phytochemicals. Phytother. Res. 2010, 24:500-502.
9. Shytle R.D., Bickford P.C., Rezai-zadeh K., Hou L., Zeng J., Tan J., Sanberg P.R., Sanberg C.D., Roschek B., Fink R.C., Alberte R.S. Optimized turmeric extracts have potent anti-amyloidogenic effects. Curr. Alzheimer Res. 2009, 6:564-571.
10. Gowda N.K., Ledoux D.R., Rottinghaus G.E., Bermudez A.J., Chen Y.C. Antioxidant efficacy of curcuminoids from turmeric (Curcuma longa L.) powder in broiler chickens fed diets containing aflatoxin B1. Br. J Nutr. 2009, 102:1629-1634.
11. Mishra K., Dash A.P., Swain B.K., Dey N. Anti-malarial activities of Andrographis paniculata and Hedyotis corymbosa extracts and their combination with curcumin. Malar. J. 2009, 8:26.
12. Mulabagal V., Calderon A.I. Development of binding assays to screen ligands for Plasmodium falciparum thioredoxin and glutathione reductases by ultrafiltration and liquid chromatography/mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878:987-993.
13. Nandakumar D.N., Nagaraj V.A., Vathsala P.G., Rangarajan P., Padmanaban G. Curcumin-artemisinin combination therapy for malaria. Antimicrob. Agents Chemother. 2006, 50:1859-1860.
14. Reddy R.C., Vatsala P.G., Keshamouni V.G., Padmanaban G., Rangarajan P.N. Curcumin for malaria therapy. Biochem. Biophys. Res. Commun. 2005, 326:472-474.
15. Jain V., Prasad V., Pal R., Singh S. Standardization and stability studies of neuroprotective lipid soluble fraction obtained from Curcuma longa. J. Pharm. Biomed. Anal. 2007, 44:1079-1086.
16. Martins S., Sarmento B., Ferreira D.C., Souto E.B. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int. J. Nanomed. 2007, 2:595-607.
17. Almeida A.J., Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 2007, 59:478-490.
18. Muller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54(Suppl. 1):S131-155.
19. Souto E.B., Muller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol. 2010, 115-141.
20. Souto E.B. A special issue on lipid-based delivery systems (liposomes, lipid nanoparticles, lipid matrices and medicines). J. Biomed. Nanotechnol. 2009, 5:315-316.
21. Souto E.B., Doktorovova S. Chapter 6-solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol. 2009, 464:105-129.
22. Aditya N.P., Patankar S., Madhusudhan B., Murthy R.S.R., Souto E.B. Arthemeter-loaded lipid nanoparticles produced by modified-thin film hydration: pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur. J. Pharm. Sci. 2010, 40:448-455.
23. Sou K., Inenaga S., Takeoka S., Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm. 2008, 352:287-293.
24. Tiyaboonchai W., Tungpradit W., Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm. 2007, 337:299-306.
25. Yallapu M.M., Maher D.M., Sundram V., Bell M.C., Jaggi M., Chauhan S.C. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian Res. 2010, 3:11.
26. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin" ): a novel strategy for human cancer therapy. J. Nanobiotechnol. 2007, 5:3.
27. Tonnesen H., Solveig K., Leonid N.G. Studies on curcumin and curcuminoids: XXV. Inhibition of primaquine-induced lysis of human red blood cells by curcumin. Int. J. Pharm. 1994, 110:161-167.
28. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
29. Jenning V., Thunemann A.F., Gohla S.H. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000, 199:167-177.
30. Teeranachaideekul V., Boonme P., Souto E.B., Muller R.H., Junyaprasert V.B. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J. Control. Release 2008, 128:134-141.
31. Vivek K., Reddy H., Murthy R.S. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007, 8:E83.
32. Manzan A.C., Toniolo F.S., Bredow E., Povh N.P. Extraction of essential oil and pigments from Curcuma longa [L] by steam distillation and extraction with volatile solvents. J. Agric. Food Chem. 2003, 51:6802-6807.
33. Ansari M.J., Ahmad S., Kohli K., Ali J., Khar R.K. Stability-indicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations. J. Pharm. Biomed. Anal. 2005, 39:132-138.
34. Heiati H., Tawashi R., Phillips N.C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization. J. Microencapsul. 1998, 15:173-184.
35. Hu F.Q., Yuan H., Zhang H.H., Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 2002, 239:121-128.
36. Ohshima H., Miyagishima A., Kurita T., Makino Y., Iwao Y., Sonobe T., Itai S. Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution. Int. J. Pharm. 2009, 377:180-184.
37. Jumaa M., Kleinebudde P., Muller B.W. Physicochemical properties and hemolytic effect of different lipid emulsion formulations using a mixture of emulsifiers. Pharm. Acta Helv. 1999, 76:293-301.
38. Zimmermann E., Muller R.H., Mader K. Influence of different parameters on reconstitution of lyophilized SLN. Int. J. Pharm. 2000, 196:211-213.
39. Li L., Braiteh F.S., Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104:1322-1331.
40. Souto E.B., Wissing S.A., Barbosa C.M., Muller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004, 278:71-77.
41. Konan Y.N., Cerny R., Favet J., Berton M., Gurny R., Allemann E. Preparation and characterization of sterile sub-200nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur. J. Pharm. Biopharm. 2003, 55:115-124.
42. Konan Y.N., Gurny R., Allemann E. Preparation and characterization of sterile and freeze-dried sub-200nm nanoparticles. Int. J. Pharm. 2002, 233:239-252.
43. Pan M.H., Huang T.M., Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 1999, 27:486-494.
44. Ireson C., Orr S., Jones D.J., Verschoyle R., Lim C.K., Luo J.L., Howells L., Plummer S., Jukes R., Williams M., Steward W.P., Gescher A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001, 61:1058-1064.
45. Krugliak M., Deharo E., Shalmiev G., Sauvain M., Moretti C., Ginsburg H. Antimalarial effects of C18 fatty acids on Plasmodium falciparum in culture and on Plasmodium vinckei petteri and Plasmodium yoelii nigeriensis in vivo. Exp. Parasitol. 1995, 81:97-105.
46. Kumaratilake L.M., Robinson B.S., Ferrante A., Poulos A. Antimalarial properties of n-3 and n-6 polyunsaturated fatty acids: in vitro effects on Plasmodium falciparum and in vivo effects on P. berghei. J. Clin. Invest. 1992, 89:961-967.
47. Varalakshmi C., Ali A.M., Pardhasaradhi B.V., Srivastava R.M., Singh S., Khar A. Immunomodulatory effects of curcumin: in-vivo. Int. Immunopharmacol. 2008, 8:688-700.
48. Singh S., Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem. 2006, 6:259-270.
49. Targett G.A. Malaria: drug use and the immune response. Parasitology 1992, 105(Suppl.):S61-70.
50. Agrawal A.K., Puri A., Haq W., Gupta C.M. Enhanced immunostimulant activity and protective effect of a synthetic lipopeptide after liposomization against Plasmodium berghei infection in mice. J. Drug Targets 2001, 9:231-239.